NCT05714072View on ClinicalTrials.gov

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Myelofibrosis Due to and Following Polycythemia Vera
Interventions
DRUG

Ruxolitinib

10mg BID or 15mg BID

DRUG

Abemaciclib

50, 100 and 150 mg

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack, Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT05714072 - A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | Biotech Hunter | Biotech Hunter